Turnstone Biologics downgraded by Piper Sandler with a new price target
$TSBX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously